menu
    • menu
    [{"orgOrder":0,"company":"Berg Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Berg Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Inapplicable"},{"orgOrder":0,"company":"BPGbio","sponsor":"Debra of America","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Partnership","leadProduct":"Ubidecarenone","moa":"LDL-cholesterol oxidation","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BPGbio \/ Debra of America","highestDevelopmentStatusID":"6","companyTruncated":"BPGbio \/ Debra of America"},{"orgOrder":0,"company":"BPGbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"LDL-cholesterol oxidation","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BPGbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Inapplicable"},{"orgOrder":0,"company":"BerGenBio ASA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase I","graph3":"BerGenBio ASA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BerGenBio ASA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BerGenBio ASA \/ Inapplicable"},{"orgOrder":0,"company":"Berg Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Berg Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Inapplicable"},{"orgOrder":0,"company":"Berg Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Berg Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Inapplicable"},{"orgOrder":0,"company":"BPGbio","sponsor":"Berg Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BPGbio \/ Berg Health","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Berg Health"},{"orgOrder":0,"company":"Berg Health","sponsor":"AdventHealth","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Collaboration","leadProduct":"Ubidecarenone","moa":"LDL-cholesterol oxidation","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Berg Health \/ AdventHealth","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ AdventHealth"},{"orgOrder":0,"company":"Berg Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ubidecarenone","moa":"||LDL-cholesterol oxidation","graph1":"Oncology","graph2":"Phase II","graph3":"Berg Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Berg Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Ubidecarenone

    Menu

    Ubidecarenone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BPGbio

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            BPGbio

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BPGbio Receives FDA Pediatric Disease Designation for Epidermolysis Bullosa Treatment

                            Details : BPM31510T (benzoquinone ubidecarenone) is an investigational treatment for epidermolysis bullosa (EB), received Rare Pediatric Disease Designation for respective indication.

                            Product Name : BPM31510

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            October 31, 2024

                            Lead Product(s) : Ubidecarenone

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BPGbio

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            BPGbio

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Berg Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510 for Glioblastoma Multiforme

                            Details : BPM 31510, the company’s lead drug candidate, acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.

                            Product Name : BPM31510

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            June 06, 2023

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Berg Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BPGbio

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            BPGbio

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Debra of America

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            BPGbio Announces Expanded Partnership with debra of America for BPM 31510 for Epidermolysis Bullosa Phase II/I...

                            Details : The collaboration is for BPGbio’s BPM 31510 for Epidermolysis Bullosa Phase II/III trial. Debra of America will provide support to awareness, understanding, and key information towards patient recruitment and advocacy for the clinical trial.

                            Product Name : BPM31510

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            March 27, 2023

                            Lead Product(s) : Ubidecarenone

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Debra of America

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Berg Health

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Berg Health

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BERG To Conduct Phase Two Trial For Treatment Of Deadly Glioblastoma Multiforme [GBM]

                            Details : Preclinical evidence in an aggressive orthotopic model of GBM suggests that pre-treatment (priming) followed by co-administration of BPM31510 in combination with standard of care, such as radiation and chemotherapy, led to an increase overall survival ra...

                            Product Name : BPM31510

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            March 22, 2021

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Berg Health

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Berg Health

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BERG to Present Phase 1 Results of BPM 31510-IV and Identifies Therapeutic Opportunities for Recurrent GBM Pat...

                            Details : Abstract titled "Comprehensive molecular pharmacodynamic assessment identifies response markers of intermediary metabolism associated with BPM31510-IV treatment in advanced glioblastoma multiforme patients" will be presented at the ASCO meeting.

                            Product Name : BPM31510

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            February 06, 2021

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Berg Health

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Berg Health

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : AdventHealth

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BERG Deepens Research Collaboration With AdventHealth To Advance Aging, Metabolism and Nash Research

                            Details : The partnership is comprised of separate investigations that employ BERG’s Interrogative Biology® platform to examine potential biomarker signatures of age-related disease. This also includes Phase II trial of BPM31510 on platelet and skeletal muscle ...

                            Product Name : BPM31510

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            December 15, 2020

                            Lead Product(s) : Ubidecarenone

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : AdventHealth

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Berg Health

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Berg Health

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BERG To Present Discovery/Validation Of Biomarkers Associated With Survival In Pancreatic Ductal Adenocarcinom...

                            Details : BPM 31510-IV (ubidecarenone) also known as coenzyme Q10 used in advanced refractory pancreatic ductal adenocarcinoma and identified two potential biomarkers overall survival and progressive disease.

                            Product Name : BPM31510

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            September 18, 2020

                            Lead Product(s) : Ubidecarenone,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Berg Health

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed

                            Berg Health

                            U.S.A arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BERG Presents Initial Clinical Data And Identification Of Response Biomarkers In A Phase 2 Pancreatic Cancer T...

                            Details : Initial results showed efficacy in patient's refractory to chemotherapy regimens and identification of potential biomarkers of survival guided by the use of the BERG Interrogative Biology® platform.

                            Product Name : BPM31510

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 27, 2020

                            Lead Product(s) : Ubidecarenone,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BerGenBio ASA

                            Norway arrow
                            Pharma Live Expo
                            Not Confirmed

                            BerGenBio ASA

                            Norway arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BERG Presents Results of Phase 1 Clinical Study in Glioblastoma at 2020 American Society of Clinical Oncology ...

                            Details : The study, presented at the 2020 American Society of Clinical Oncology Annual Meeting (ASCO), highlights safety, tolerability and the impact of BPM 31510-IV influence on metabolism in patients, supporting planned Phase 2 clinical development.

                            Product Name : BPM31510

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 06, 2020

                            Lead Product(s) : Ubidecarenone,Temozolomide,Vitamin K1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth